Robert Rissman

Dr. Rissman is Professor Physiology and Neuroscience and the W.M. Keck Endowed Chair in Medicine at the University of Southern California (USC). He is the founding Director of the Neuroscience Translational Research Division (NTRD) at USC’s San Diego campus, Alzheimer’s Therapeutic Research Institute (ATRI). Concurrently with his research, Dr. Rissman also serves as the Biomarker Unit Lead for the Alzheimer’s Clinical Trials Consortium (ACTC) and USC’s Alzheimer’s Disease Research Center. The NTRD is comprised by a wet laboratory space and a large biorepository of -80 freezers to store specimens from clinical trials and longitudinal cohort studies. Using biobanked human specimens, animal and cell models, the goal of Dr. Rissman’s basic science research is to identify and validate plasma biomarkers for Alzheimer’s Disease and Related Disorders (ADRD) to better understand mechanisms of neurodegeneration and to streamline clinical trials recruitment. Work from Dr. Rissman’s lab has led to the validation of plasma biomarkers that predict AD brain neuropathology and progression of dementia and through analysis of plasma-derived extracellular vesicles, his group was also the first to demonstrate that TDP-43 protein within astrocyte extracellular vesicles can identify Limbic-predominant age-related TDP-43 encephalopathy (LATE). Using animal and cell culture models, Dr. Rissman’s lab is focused on understanding how synucleinopathy and other common comorbidities in AD can be identified and treated.

• Journal of Alzheimer’s Disease: Mark Smith Alzheimer’s Award, 2024

• Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease Neurology. 2025 Jan 14; 104(1):e210152. . View in PubMed
• Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer’s disease detection J Alzheimers Dis. 2024 Dec; 102(3):659-669. . View in PubMed
• A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species Brain. 2024 Nov 04; 147(11):3890-3905. . View in PubMed
• Clinical and neuropathological analysis of Down syndrome over 7 decades of life J Neuropathol Exp Neurol. 2024 Oct 29. . View in PubMed
• Epigenetic and genetic risk of Alzheimer disease from autopsied brains in two ethnic groups Acta Neuropathol. 2024 Aug 23; 148(1):27. . View in PubMed
• The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study medRxiv. 2024 Aug 22. . View in PubMed
• Testing the causal impact of amyloidosis on total Tau using a genetically informative sample of adult male twins bioRxiv. 2024 Jul 26. . View in PubMed
• Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome Sequencing medRxiv. 2024 Jun 25. . View in PubMed
• Immunotherapy with an antibody against CD1d modulates neuroinflammation in an a-synuclein transgenic model of Lewy body like disease J Neuroinflammation. 2024 Apr 15; 21(1):93. . View in PubMed
• From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer’s disease for targeted therapeutic approach Alzheimers Dement (Amst). 2024 Apr-Jun; 16(2):e12580. . View in PubMed
• CSF1R-mediated myeloid cell depletion shifts the ratio of motor cortical excitatory to inhibitory neurons in a multiple system atrophy model Exp Neurol. 2024 Apr; 374:114706. . View in PubMed
• AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer’s disease bioRxiv. 2024 Mar 27. . View in PubMed
• A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease medRxiv. 2024 Mar 22. . View in PubMed
• Multi-omics Characterization of Epigenetic and Genetic Risk of Alzheimer Disease in Autopsied Brains from two Ethnic Groups medRxiv. 2024 Feb 14. . View in PubMed
• Corrigendum to ” Systemic peptide mediated delivery of an siRNA targeting a-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy Body Disease” [Neurobiology of Disease127 (2019) 163-177] Neurobiol Dis. 2024 Feb; 191:106397. . View in PubMed
• Correction: GP120 and tenofovir alafenamide alter cannabinoid receptor 1 expression in hippocampus of mice J Neurovirol. 2024 Feb; 30(1):101-102. . View in PubMed
• Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: An international overview Alzheimers Dement. 2024 07; 20(7):4411-4422. . View in PubMed
• Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial Alzheimers Dement. 2024 06; 20(6):3827-3838. . View in PubMed
• Amyloid precursor protein induces reactive astrogliosis Acta Physiol (Oxf). 2024 06; 240(6):e14142. . View in PubMed
• Plasma Aß42/Aß40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease Alzheimers Dement. 2024 02; 20(2):1214-1224. . View in PubMed
• Association between military service and Alzheimer’s disease neuropathology at autopsy Alzheimers Dement. 2024 02; 20(2):1468-1474. . View in PubMed
• The heritability of blood-based biomarkers related to risk of Alzheimer’s disease in a population-based sample of early old-age men Alzheimers Dement. 2024 01; 20(1):356-365. . View in PubMed
• Retina pathology as a target for biomarkers for Alzheimer’s disease: Current status, ophthalmopathological background, challenges, and future directions Alzheimers Dement. 2024 01; 20(1):728-740. . View in PubMed
• Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies J Prev Alzheimers Dis. 2024; 11(4):802-813. . View in PubMed
• Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4 J Prev Alzheimers Dis. 2024; 11(4):831-837. . View in PubMed
• Maximizing the Utility of Alzheimer’s Disease Trial Data: Sharing of Baseline A4 and LEARN Data J Prev Alzheimers Dis. 2024; 11(4):889-894. . View in PubMed
• Midlife cumulative deficit frailty predicts Alzheimer’s disease-related plasma biomarkers in older adults Age Ageing. 2024 03 01; 53(3). . View in PubMed
• Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men Alzheimers Res Ther. 2024 04 25; 16(1):90. . View in PubMed
• Characterization of Ptau181 Among a Diverse Community-Based Cohort: A HABS-HD Study J Alzheimers Dis. 2024; 100(s1):S63-S73. . View in PubMed
• A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease Alzheimers Res Ther. 2024 07 05; 16(1):151. . View in PubMed
• Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer’s Disease J Prev Alzheimers Dis. 2024; 11(4):823-830. . View in PubMed
• The neuropathological landscape of small vessel disease and Lewy pathology in a cohort of Hispanic and non-Hispanic White decedents with Alzheimer disease Acta Neuropathol Commun. 2024 05 24; 12(1):81. . View in PubMed
• Amyloid precursor protein induces reactive astrogliosis bioRxiv. 2023 Dec 18. . View in PubMed
• Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: An international overview bioRxiv. 2023 Oct 02. . View in PubMed
• Differential involvement of hippocampal subfields in the relationship between Alzheimer’s pathology and memory interference in older adults Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12419. . View in PubMed
• Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12451. . View in PubMed
• The Independent Walking for Brain Health Intervention for Older Adults: Protocol for a Pilot Randomized Controlled Trial JMIR Res Protoc. 2023 Feb 13; 12:e42980. . View in PubMed
• Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer’s disease: Research outline and call for collaboration Alzheimers Dement. 2023 11; 19(11):5209-5231. . View in PubMed
• GP120 and tenofovir alafenamide alter cannabinoid receptor 1 expression in hippocampus of mice J Neurovirol. 2023 10; 29(5):564-576. . View in PubMed
• Pathogenesis of Alzheimer’s disease: Involvement of the choroid plexus Alzheimers Dement. 2023 08; 19(8):3537-3554. . View in PubMed
• Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer’s disease Alzheimers Dement. 2023 05; 19(5):2084-2094. . View in PubMed
• The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer’s disease Alzheimers Dement. 2023 04; 19(4):1227-1233. . View in PubMed
• Missorting of plasma miRNAs in aging and Alzheimer’s disease J Neurochem. 2023 04; 165(2):149-161. . View in PubMed
• Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy Neurobiol Dis. 2023 03; 178:106010. . View in PubMed
• LATE-NC staging in routine neuropathologic diagnosis: an update Acta Neuropathol. 2023 02; 145(2):159-173. . View in PubMed
• Diminished Neuronal ESCRT-0 Function Exacerbates AMPA Receptor Derangement and Accelerates Prion-Induced Neurodegeneration J Neurosci. 2023 05 24; 43(21):3970-3984. . View in PubMed
• Association of cardiovascular risk factors and blood biomarkers with cognition: The HABS-HD study Alzheimers Dement (Amst). 2023 Jan-Mar; 15(1):e12394. . View in PubMed
• Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin Extracell Vesicles Circ Nucl Acids. 2023; 4(4):588-598. . View in PubMed
• Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce a-synuclein in a mouse model of Alzheimer’s disease Neurobiol Dis. 2023 10 01; 186:106285. . View in PubMed
• Evaluation of Neighborhood-Level Disadvantage and Cognition in Mexican American and Non-Hispanic White Adults 50 Years and Older in the US JAMA Netw Open. 2023 08 01; 6(8):e2325325. . View in PubMed
• TDP-43 Pathology in the Setting of Intermediate and High Alzheimer’s Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups J Alzheimers Dis. 2023; 91(4):1291-1301. . View in PubMed
• Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study J Alzheimers Dis. 2023; 95(4):1609-1622. . View in PubMed
• Front Neurol. 2023; 14:1331194. . View in PubMed
• Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease J Alzheimers Dis. 2023; 92(1):95-107. . View in PubMed
• Sci Transl Med. 2023 05 10; 15(695):eabq6089. . View in PubMed
• Characterization of altered molecular mechanisms in Parkinson’s disease through cell type-resolved multiomics analyses Sci Adv. 2023 04 14; 9(15):eabo2467. . View in PubMed
• D-685 Reverses Motor Deficits and Reduces Accumulation of Human a-Synuclein Protein in Two Different Parkinson’s Disease Animal Models ACS Chem Neurosci. 2023 03 01; 14(5):885-896. . View in PubMed
• Hippocampal Reduction of a-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice J Alzheimers Dis. 2023; 95(1):349-361. . View in PubMed
• The neuropathological landscape of Hispanic and non-Hispanic White decedents with Alzheimer disease Acta Neuropathol Commun. 2023 06 29; 11(1):105. . View in PubMed
• Nicotine-mediated effects in neuronal and mouse models of synucleinopathy Front Neurosci. 2023; 17:1239009. . View in PubMed
• SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer’s-like neuropathology bioRxiv. 2022 Sep 06. . View in PubMed
• Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change Acta Neuropathol. 2022 04; 143(4):487-503. . View in PubMed
• Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study Alzheimers Dement. 2022 02; 18(2):240-250. . View in PubMed
• Genome-wide association study and functional validation implicates JADE1 in tauopathy Acta Neuropathol. 2022 01; 143(1):33-53. . View in PubMed
• A blood screening tool for detecting mild cognitive impairment and Alzheimer’s disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research Alzheimers Dement. 2022 01; 18(1):77-87. . View in PubMed
• Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial Sci Rep. 2022 01 25; 12(1):1346. . View in PubMed
• CSF1R-Mediated Myeloid Cell Depletion Prolongs Lifespan But Aggravates Distinct Motor Symptoms in a Model of Multiple System Atrophy J Neurosci. 2022 10 05; 42(40):7673-7688. . View in PubMed
• Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies J Neuropathol Exp Neurol. 2022 11 16; 81(12):953-964. . View in PubMed
• Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites J Alzheimers Dis. 2022; 90(2):905-915. . View in PubMed
• Association of neurofilament light chain with renal function: mechanisms and clinical implications Alzheimers Res Ther. 2022 12 16; 14(1):189. . View in PubMed
• Modulation of Amyloid-ß and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil J Alzheimers Dis. 2022; 90(2):705-717. . View in PubMed
• Evaluation of blood-based, extracellular vesicles as biomarkers for aging-related TDP-43 pathology Alzheimers Dement (Amst). 2022; 14(1):e12365. . View in PubMed
• Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer J Alzheimers Dis. 2022; 88(3):1137-1145. . View in PubMed
• Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer’s Disease Brain ACS Chem Neurosci. 2022 07 06; 13(13):1992-2005. . View in PubMed
• Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial JAMA Neurol. 2022 06 01; 79(6):565-574. . View in PubMed
• Association of Neighborhood-Level Disadvantage With Neurofibrillary Tangles on Neuropathological Tissue Assessment JAMA Netw Open. 2022 04 01; 5(4):e228966. . View in PubMed
• Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels Commun Biol. 2022 04 08; 5(1):336. . View in PubMed
• Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study J Alzheimers Dis. 2022; 86(3):1243-1254. . View in PubMed
• The Link between APOE4 Presence and Neuropsychological Test Performance among Mexican Americans and Non-Hispanic Whites of the Multiethnic Health & Aging Brain Study – Health Disparities Cohort Dement Geriatr Cogn Disord. 2022; 51(1):26-31. . View in PubMed
• Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study Alzheimers Dement (Amst). 2022; 14(1):e12267. . View in PubMed
• Dopamine neurons exhibit emergent glutamatergic identity in Parkinson’s disease Brain. 2022 04 29; 145(3):879-886. . View in PubMed
• Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer’s Disease and Related Dementias Methods Mol Biol. 2022; 2383:447-457. . View in PubMed
• Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study Neurology. 2022 02 01; 98(5):e506-e517. . View in PubMed
• Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons ACS Omega. 2021 May 25; 6(20):13033-13056. . View in PubMed
• Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer’s disease Alzheimers Dement. 2021 09; 17(9):1487-1498. . View in PubMed
• Mutant three-repeat tau expression initiates retinal ganglion cell death through Caspase-2 Neurobiol Dis. 2021 05; 152:105277. . View in PubMed
• Effects of innate immune receptor stimulation on extracellular a-synuclein uptake and degradation by brain resident cells Exp Mol Med. 2021 02; 53(2):281-290. . View in PubMed
• Unbalanced Regulation of a7 nAChRs by Ly6h and NACHO Contributes to Neurotoxicity in Alzheimer’s Disease J Neurosci. 2021 10 13; 41(41):8461-8474. . View in PubMed
• Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial Alzheimers Dement (Amst). 2021; 13(1):e12199. . View in PubMed
• Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes Front Neurol. 2021; 12:698206. . View in PubMed
• The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics Alzheimers Dement (Amst). 2021; 13(1):e12202. . View in PubMed
• Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease J Prev Alzheimers Dis. 2021; 8(3):240-248. . View in PubMed
• Protein Footprinting via Covalent Protein Painting Reveals Structural Changes of the Proteome in Alzheimer’s Disease J Proteome Res. 2021 05 07; 20(5):2762-2771. . View in PubMed
• A Precision Medicine Approach to Treating Alzheimer’s Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials J Alzheimers Dis. 2021; 81(2):557-568. . View in PubMed
• J Exp Med. 2021 04 05; 218(4). . View in PubMed
• NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression Cells. 2021 12 13; 10(12). . View in PubMed
• Using Fractional Anisotropy Imaging to Detect Mild Cognitive Impairment and Alzheimer’s Disease among Mexican Americans and Non-Hispanic Whites: A HABLE Study Dement Geriatr Cogn Disord. 2021; 50(3):266-273. . View in PubMed
• Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expression PLoS One. 2021; 16(9):e0251611. . View in PubMed
• A transcriptome-wide association study of Alzheimer’s disease using prediction models of relevant tissues identifies novel candidate susceptibility genes Genome Med. 2021 09 01; 13(1):141. . View in PubMed
• Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy J Neuropathol Exp Neurol. 2021 01 20; 80(2):102-111. . View in PubMed
• Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer’s disease Science. 2021 01 15; 371(6526). . View in PubMed
• Reproductive status impact on tau phosphorylation induced by chronic stress Neurobiol Stress. 2020 Nov; 13:100241. . View in PubMed
• Neuroinflammation is associated with infiltration of T cells in Lewy body disease and a-synuclein transgenic models J Neuroinflammation. 2020 Jul 17; 17(1):214. . View in PubMed
• Transcriptomic analysis of brain tissues identifies a role for CCAAT enhancer binding protein ß in HIV-associated neurocognitive disorder J Neuroinflammation. 2020 Apr 11; 17(1):112. . View in PubMed
• A missense point mutation in nerve growth factor (NGFR100W) results in selective peripheral sensory neuropathy Prog Neurobiol. 2020 11; 194:101886. . View in PubMed
• Nature. 2020 10; 586(7831):735-740. . View in PubMed
• Cathepsin B in neurodegeneration of Alzheimer’s disease, traumatic brain injury, and related brain disorders Biochim Biophys Acta Proteins Proteom. 2020 08; 1868(8):140428. . View in PubMed
• Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses Mol Cell Proteomics. 2020 06; 19(6):1017-1034. . View in PubMed
• Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease Transl Neurodegener. 2020 06 18; 9(1):26. . View in PubMed
• DTI-identified microstructural changes in the gray matter of mice overexpressing CRF in the forebrain Psychiatry Res Neuroimaging. 2020 10 30; 304:111137. . View in PubMed
• Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate a-synuclein pathology Acta Neuropathol Commun. 2020 08 04; 8(1):123. . View in PubMed
• The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview J Prev Alzheimers Dis. 2020; 7(4):208-212. . View in PubMed
• LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies Sci Transl Med. 2020 10 14; 12(565). . View in PubMed
• The Area Deprivation Index: A novel tool for harmonizable risk assessment in Alzheimer’s disease research Alzheimers Dement (N Y). 2020; 6(1):e12039. . View in PubMed
• Association of Neighborhood-Level Disadvantage With Alzheimer Disease Neuropathology JAMA Netw Open. 2020 06 01; 3(6):e207559. . View in PubMed
• Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau Brain Commun. 2020; 2(1):fcaa025. . View in PubMed
• Front Neurosci. 2020; 14:286. . View in PubMed
• Plasma Levels of Neuron- and Astrocyte-Derived Exosomal Amyloid Beta1-42, Amyloid Beta1-40, and Phosphorylated Tau Levels in Schizophrenia Patients and Non-psychiatric Comparison Subjects: Relationships With Cognitive Functioning and Psychopathology Front Psychiatry. 2020; 11:532624. . View in PubMed
• Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume JAMA Neurol. 2020 04 01; 77(4):451-460. . View in PubMed
• The GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer’s Disease J Alzheimers Dis. 2020; 73(4):1541-1554. . View in PubMed
• Diverse proteins aggregate in mild cognitive impairment and Alzheimer’s disease brain Alzheimers Res Ther. 2020 06 19; 12(1):75. . View in PubMed
• Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial JAMA Neurol. 2020 09 01; 77(9):1099-1109. . View in PubMed
• Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer’s disease dementia Alzheimers Dement (Amst). 2019 Dec; 11:61-66. . View in PubMed
• Reflections on the Utility of the Retina as a Biomarker for Alzheimer’s Disease: A Literature Review Neurol Ther. 2019 Dec; 8(Suppl 2):57-72. . View in PubMed
• Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial JAMA Neurol. 2019 Nov 01; 76(11):1330-1339. . View in PubMed
• Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2019 Oct 01; 76(10):1219-1229. . View in PubMed
• High-Throughput Mass Spectrometry Assay for Quantifying ß-Amyloid 40 and 42 in Cerebrospinal Fluid Clin Chem. 2019 12; 65(12):1572-1580. . View in PubMed
• Effects of single and combined immunotherapy approach targeting amyloid ß protein and a-synuclein in a dementia with Lewy bodies-like model Alzheimers Dement. 2019 09; 15(9):1133-1148. . View in PubMed
• Systemic peptide mediated delivery of an siRNA targeting a-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease Neurobiol Dis. 2019 07; 127:163-177. . View in PubMed
• Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD Acta Neuropathol. 2019 06; 137(6):879-899. . View in PubMed
• Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer’s disease Alzheimers Dement. 2019 03; 15(3):487-496. . View in PubMed
• Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need Alzheimers Dement. 2019 02; 15(2):292-312. . View in PubMed
• Early neuronal accumulation of DNA double strand breaks in Alzheimer’s disease Acta Neuropathol Commun. 2019 05 17; 7(1):77. . View in PubMed
• Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI) J Alzheimers Dis. 2019; 70(1):131-138. . View in PubMed
• Extracellular Vesicles Isolated from Familial Alzheimer’s Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain J Alzheimers Dis. 2019; 72(2):575-585. . View in PubMed
• miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer’s Patients Front Neurosci. 2019; 13:1208. . View in PubMed
• Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report Brain. 2019 06 01; 142(6):1503-1527. . View in PubMed
• Brain cell type-specific enhancer-promoter interactome maps and disease-risk association Science. 2019 11 29; 366(6469):1134-1139. . View in PubMed
• Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity Front Neurosci. 2019; 13:1005. . View in PubMed
• Neuronal Exosome-Derived Human Tau is Toxic to Recipient Mouse Neurons in vivo J Alzheimers Dis. 2019; 67(2):541-553. . View in PubMed
• Integrating Gene and Protein Expression Reveals Perturbed Functional Networks in Alzheimer’s DiseaseCell Rep. 2019 07 23; 28(4):1103-1116. e4. . View in PubMed
• T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation Traffic. 2018 11; 19(11):840-853. . View in PubMed
• Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders Acta Neuropathol. 2018 07; 136(1):69-87. . View in PubMed
• Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study Lancet Neurol. 2018 06; 17(6):548-558. . View in PubMed
• Clinical-Neuropathological Correlations of Alzheimer’s Disease and Related Dementias in Latino Volunteers J Alzheimers Dis. 2018; 66(4):1539-1548. . View in PubMed
• Targeted Mutation (R100W) of the Gene Encoding NGF Leads to Deficits in the Peripheral Sensory Nervous System Front Aging Neurosci. 2018; 10:373. . View in PubMed
• Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies Sci Rep. 2018 12 27; 8(1):18083. . View in PubMed
• Growth Hormone-Releasing Hormone Modulation of Neuronal Exosome Biomarkers in Mild Cognitive Impairment J Alzheimers Dis. 2018; 66(3):971-981. . View in PubMed
• A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer’s Disease J Alzheimers Dis. 2018; 66(1):97-104. . View in PubMed
• Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating a-synuclein transmission and neuroinflammation Mol Neurodegener. 2018 08 09; 13(1):43. . View in PubMed
• Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2018 07 01; 75(7):834-841. . View in PubMed
• Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau J Alzheimers Dis. 2018; 61(3):1201-1219. . View in PubMed
• Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies J Neurosci. 2018 01 24; 38(4):1000-1014. . View in PubMed
• Nat Med. 2017 Nov; 23(11):1377-1383. . View in PubMed
• Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation Neurobiol Dis. 2017 Oct; 106:222-234. . View in PubMed
• Differential effects of immunotherapy with antibodies targeting a-synuclein oligomers and fibrils in a transgenic model of synucleinopathy Neurobiol Dis. 2017 Aug; 104:85-96. . View in PubMed
• A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2017 May 02; 88(18):1768-1775. . View in PubMed
• J Pharmacol Exp Ther. 2017 07; 362(1):31-44. . View in PubMed
• Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic Alzheimers Dement. 2017 01; 13(1):45-58. . View in PubMed
• Brain-derived exosomes from dementia with Lewy bodies propagate a-synuclein pathology Acta Neuropathol Commun. 2017 06 09; 5(1):46. . View in PubMed
• NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism Nat Commun. 2017 11 14; 8(1):1488. . View in PubMed
• Lack of Influence of Apolipoprotein E Status on Cognition or Brain Structure in Professional Fighters J Neurotrauma. 2017 01 15; 34(2):380-384. . View in PubMed
• PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI) J Alzheimers Dis. 2017; 60(2):439-450. . View in PubMed
• Corticotropin-releasing factor receptor-1 modulates biomarkers of DNA oxidation in Alzheimer’s disease mice PLoS One. 2017; 12(7):e0181367. . View in PubMed
• Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease Sci Rep. 2017 06 20; 7(1):3868. . View in PubMed
• Anti-a-synuclein immunotherapy reduces a-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy Acta Neuropathol Commun. 2017 01 13; 5(1):7. . View in PubMed
• Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease J Neuroinflammation. 2017 01 03; 14(1):1. . View in PubMed
• Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment J Alzheimers Dis. 2017; 56(1):229-237. . View in PubMed
• Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer’s disease Alzheimers Dement (N Y). 2016 Jun; 2(2):131-139. . View in PubMed
• Dissociation of Down syndrome and Alzheimer’s disease effects with imaging Alzheimers Dement (N Y). 2016 Jun; 2(2):69-81. . View in PubMed
• Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer’s disease Alzheimers Dement. 2016 05; 12(5):527-37. . View in PubMed
• Higher Brain Perfusion May Not Support Memory Functions in Cognitively Normal Carriers of the ApoE e4 Allele Compared to Non-Carriers Front Aging Neurosci. 2016; 8:151. . View in PubMed
• Reducing Endogenous a-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer’s Disease Transgenic Mouse Model J Neurosci. 2016 07 27; 36(30):7971-84. . View in PubMed
• Meditation and vacation effects have an impact on disease-associated molecular phenotypes Transl Psychiatry. 2016 08 30; 6(8):e880. . View in PubMed
• Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport PLoS One. 2016; 11(1):e0147250. . View in PubMed
• Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile Alzheimers Dement (Amst). 2016; 3:63-72. . View in PubMed
• Comparing biological markers of Alzheimer’s disease across blood fraction and platforms: Comparing apples to oranges Alzheimers Dement (Amst). 2016; 3:27-34. . View in PubMed
• Reproductive Stage and Modulation of Stress-Induced Tau Phosphorylation in Female Rats J Neuroendocrinol. 2015 Nov; 27(11):827-34. . View in PubMed
• A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neurology. 2015 Oct 20; 85(16):1383-91. . View in PubMed
• Longitudinal plasma amyloid beta in Alzheimer’s disease clinical trials Alzheimers Dement. 2015 Sep; 11(9):1069-79. . View in PubMed
• Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker Alzheimers Dement (Amst). 2015 Sep; 1(3):311-315. . View in PubMed
• Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research Alzheimers Dement. 2015 May; 11(5):549-60. . View in PubMed
• Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor J Alzheimers Dis. 2015; 43(3):967-76. . View in PubMed
• Elevated cerebrovascular resistance index is associated with cognitive dysfunction in the very-old Alzheimers Res Ther. 2015 01 21; 7(1):3. . View in PubMed
• The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome Front Behav Neurosci. 2015; 9:239. . View in PubMed
• Characterization of ATP alternations in an Alzheimer’s disease transgenic mouse model J Alzheimers Dis. 2015; 44(2):375-8. . View in PubMed
• J Alzheimers Dis. 2015; 48(1):205-18. . View in PubMed
• Impact of CRFR1 Ablation on Amyloid-ß Production and Accumulation in a Mouse Model of Alzheimer’s Disease J Alzheimers Dis. 2015; 45(4):1175-84. . View in PubMed
• Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model J Alzheimers Dis. 2015; 45(2):639-50. . View in PubMed
• Long-Term Electrophysiological and Behavioral Analysis on the Improvement of Visual Working Memory Load, Training Gains, and Transfer Benefits J Behav Brain Sci. 2014 May 01; 4(5):234-246. . View in PubMed
• Detection and quantification of 8-hydroxy-2′-deoxyguanosine in Alzheimer’s transgenic mouse urine using capillary electrophoresis Electrophoresis. 2013 Aug; 34(15):2268-74. . View in PubMed
• CSF biomarker variability in the Alzheimer’s Association quality control program Alzheimers Dement. 2013 May; 9(3):251-61. . View in PubMed
• Cortical and subcortical cerebrovascular resistance index in mild cognitive impairment and Alzheimer’s disease J Alzheimers Dis. 2013; 36(4):689-98. . View in PubMed
• Interaction of age and APOE genotype on cerebral blood flow at rest J Alzheimers Dis. 2013; 34(4):921-35. . View in PubMed
• Effect of mild cognitive impairment and APOE genotype on resting cerebral blood flow and its association with cognition J Cereb Blood Flow Metab. 2012 Aug; 32(8):1589-99. . View in PubMed
• Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. . View in PubMed
• Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6277-82. . View in PubMed
• Lipopolysaccharide-induced tau phosphorylation and kinase activity–modulation, but not mediation, by corticotropin-releasing factor receptors Eur J Neurosci. 2011 Aug; 34(3):448-56. . View in PubMed
• The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkersAlzheimers Dement. 2011 Jul; 7(4):386-395. e6. . View in PubMed
• Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer’s disease J Neurochem. 2011 May; 117(4):613-22. . View in PubMed
• Functional amyloids as natural storage of peptide hormones in pituitary secretory granules Science. 2009 Jul 17; 325(5938):328-32. . View in PubMed
• Stress-induced tau phosphorylation: functional neuroplasticity or neuronal vulnerability? J Alzheimers Dis. 2009; 18(2):453-7.. View in PubMed
• GABA(A) receptors in aging and Alzheimer’s disease J Neurochem. 2007 Nov; 103(4):1285-92. . View in PubMed
• Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation J Neurosci. 2007 Jun 13; 27(24):6552-62. . View in PubMed
• Age-related alterations in GABA(A) receptor subunits in the nonhuman primate hippocampus Brain Res. 2006 Feb 16; 1073-1074:120-30. . View in PubMed
• Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology Acta Neuropathol. 2005 Aug; 110(2):135-44. . View in PubMed
• The role of caspase cleavage of tau in Alzheimer disease neuropathology J Neuropathol Exp Neurol. 2005 Feb; 64(2):104-12. . View in PubMed
• Subregional analysis of GABA(A) receptor subunit mRNAs in the hippocampus of older persons with and without cognitive impairment J Chem Neuroanat. 2004 Sep; 28(1-2):17-25. . View in PubMed
• Caspase-mediated degeneration in Alzheimer’s disease Am J Pathol. 2004 Aug; 165(2):353-5. . View in PubMed
• Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology J Clin Invest. 2004 Jul; 114(1):121-30. . View in PubMed
• Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer’s disease patients according to Braak stage Exp Neurol. 2004 Jun; 187(2):299-309. . View in PubMed
• Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer’s disease pathology Neurobiol Dis. 2004 Feb; 15(1):80-92. . View in PubMed
• Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer’s disease Cell Mol Neurobiol. 2003 Oct; 23(4-5):491-505. . View in PubMed
• Biochemical analysis of GABA(A) receptor subunits alpha 1, alpha 5, beta 1, beta 2 in the hippocampus of patients with Alzheimer’s disease neuropathology Neuroscience. 2003; 120(3):695-704. . View in PubMed
• Caspase Activation in the Alzheimer’s Disease Brain: Tortuous and Torturous Drug News Perspect. 2002 Nov; 15(9):549-557. . View in PubMed
• Caspase-9 activation and caspase cleavage of tau in the Alzheimer’s disease brain Neurobiol Dis. 2002 Nov; 11(2):341-54. . View in PubMed
• Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors J Comp Neurol. 1999 Dec 20; 415(3):285-312. . View in PubMed

• Aisen, Paul
• Zlokovic, Berislav
• Thompson, Paul
• Toga, Arthur
• Schneider, Lon
• Ringman, John
• Rafii, Michael